For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Dabigatran etexilate - Deep Vein Thrombosis (DVT) / Pulmonary Embolism (PE)
PAD Profile : Dabigatran etexilate - Deep Vein Thrombosis (DVT) / Pulmonary Embolism (PE)
Traffic Light Status
Status 1 of 1.
- Capsules
Guidelines
No guidelines returned.
Other Drugs
Other Indications
- Atrial fibrillation
- VTE prevention post hip/knee replacement
- VTE treatment and prevention (children)
Additional Documents
Committee Recommendations
The Surrey Heartlands integrated care system Area Prescribing Committee (APC) have made the following recommendations for the implementation of the NICE guideline - Venous Thromboembolic Diseases: diagnosis, management and thrombophilia testing (NG158):
1. Apixaban, rivaroxaban, edoxaban and dabigatran were assigned a BLUE (no information sheet) traffic light status with:
- Apixaban or rivaroxoaban for initiation in most patients because they do not require initial treatment with 5 days of LMWH
- Edoxaban and dabigatran reserved for those few patients who are not clinically suitable for apixaban or rivaroxaban eg those with excellent renal function where dabigatran is the best choice.
2. Specialist to prescribe the first month of treatment
3. Specialist to request transfer of prescribing to primary care using the transfer of prescribing document (see below)
4. The NICE & South West London pathways for VTE diagnosis and management are available below for reference
The Surrey & North West Sussex Area Prescribing Committee have agreed a Creatinine Clearance calculator for reference by prescribers. Please see below